Publications by authors named "A D Narezkina"
Article Synopsis
- Immune-checkpoint inhibitors (ICIs) can lead to serious heart issues like myocarditis, which can also involve broader muscle-related symptoms, highlighting the need for understanding associated risks.
- A study conducted across 17 countries from 2014 to 2023 examined data from 748 patients to identify factors that predict severe outcomes related to these heart complications, using a statistical model for analysis.
- Key findings indicated that certain conditions (like active thymoma) and symptoms (like low heart function) significantly increased the risk of severe heart-related events, and a risk score created from these factors effectively predicted outcomes, validated in multiple cohorts.
Article Synopsis
- - The case study discusses a patient with pancreatic carcinoma characterized by NTRK fusion positivity, which means the cancer cells have a specific genetic alteration.
- - The patient also suffers from congenital long QT syndrome, a heart condition that can lead to serious irregular heartbeats, complicating treatment options.
- - Repotrectinib, a targeted therapy drug designed to inhibit NTRK fusion proteins, was administered to the patient, aiming to address both the cancer and the patient's unique health challenges.
Patients who undergo implantation of a left ventricular assist device (LVAD) are at a high risk for right ventricular failure (RVF), presumably due to poor right ventricular (RV) function before surgery. Cine computerized tomography (cineCT) can be used to evaluate RV size, function, and endocardial strain. However, CT-based strain measures in patients undergoing workup for LVAD implantation have not been evaluated.
View Article and Find Full Text PDFBackground: Multiple myeloma is often complicated by pulmonary hypertension through a variety of mechanisms. These mechanisms include pulmonary hypertension (PH) due to concomitant cardiac amyloid, high output heart failure due to anemia or lytic bone lesions, chronic thromboembolic pulmonary hypertension (CTEPH), toxicity from medications to treat multiple myeloma, and congestive heart failure. This case series highlights the various mechanisms through which multiple myeloma patients develop pulmonary hypertension.
View Article and Find Full Text PDF